2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA VALIDATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH 3 AVAILABLE TKIS OUTSIDE CLINICAL TRIALS

被引：0
|
作者：
Breccia, M. [1 ]
Pregno, P. [2 ]
Annunziata, M. [3 ]
Orlandi, E. [4 ]
Gozzini, A. [5 ]
Iurlo, A. [6 ]
Bocchia, M. [7 ]
Franceschini, L. [8 ]
Montefusco, E. [9 ]
Crugnola, M. [10 ]
La Nasa, G. [11 ]
Scortechini, A. R. [12 ]
Sgherza, N. [13 ]
Sica, S. [14 ]
Alimena, G. [1 ]
Saglio, G. [15 ]
Specchia, G. [16 ]
机构：
[1] Univ Roma La Sapienza, Hematol, Dept Cellular Biotechnol & Hematol, Rome, Italy
[2] Citta Salute & Sci Torino AOU, Hematol, Turin, Italy
[3] Cardarelli Hosp, Hematol, Naples, Italy
[4] Fdn IRCSS Policlin San Matteo, Hematol, Pavia, Italy
[5] Careggi Hosp AOU, Hematol, Florence, Italy
[6] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Hematol, Milan, Italy
[7] Univ Siena, Hematol, Siena, Italy
[8] Univ Roma Tor Vergata, Rome, Italy
[9] S Andrea Hosp, Hematol, Rome, Italy
[10] Parma AOU, Hematol, Parma, Italy
[11] Univ Cagliari, Hematol, Dept Med Sci, Cagliari, Italy
[12] Osped Riuniti Ancona, Hematol, Ancona, Italy
[13] IRCSS Ist Tumori Giovanni Paolo II, Hematol, Bari, Italy
[14] Univ Cattolica, Hematol, Rome, Italy
[15] Univ Turin, Hematol, Turin, Italy
[16] Policlin Consorziale Bari AOU, Hematol, Bari, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1827
引用
收藏
页码：738 / 739
页数：2
相关论文
共 50 条
  • [11] THE RESULTS OF TYROSINE-KINASE INHIBITORS TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS ACCORDING TO 2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA: RUSSIAN SINGLE-CENTER STUDY
    Shukhov, O.
    Turkina, A.
    Chelysheva, E.
    Gusarova, G.
    Nemchenko, I.
    Bykova, A.
    Abdullaev, A.
    HAEMATOLOGICA, 2016, 101 : 744 - 744
  • [12] The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia
    Noriyoshi Iriyama
    Yoshihiro Hatta
    Sumiko Kobayashi
    Yoshihito Uchino
    Katsuhiro Miura
    Daisuke Kurita
    Hitomi Kodaira
    Mitsuru Inoue
    Masami Takei
    International Journal of Hematology, 2014, 100 : 379 - 385
  • [13] The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia
    Iriyama, Noriyoshi
    Hatta, Yoshihiro
    Kobayashi, Sumiko
    Uchino, Yoshihito
    Miura, Katsuhiro
    Kurita, Daisuke
    Kodaira, Hitomi
    Inoue, Mitsuru
    Takei, Masami
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (04) : 379 - 385
  • [14] Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study
    Stagno, Fabio
    Breccia, Massimo
    Annunziata, Mario
    Trawinska, Malgorzata Monika
    Iurlo, Alessandra
    Sgherza, Nicola
    Fava, Carmen
    Gozzini, Antonella
    Luciano, Luigiana
    Carmosino, Ida
    Bonifacio, Massimiliano
    Sora, Federica
    Crescenzi, Sabrina Leonetti
    Crugnola, Monica
    Gugliotta, Gabriele
    Galimberti, Sara
    Bucelli, Cristina
    Colafigli, Gioia
    Feo, Costanzo
    Tiribelli, Mario
    Mauro, Endri
    Rossi, Antonella Russo
    Guarini, Attilio
    Abruzzese, Elisabetta
    Rosti, Gianantonio
    Di Raimondo, Francesco
    Latagliata, Roberto
    ACTA ONCOLOGICA, 2021, 60 (11) : 1527 - 1533
  • [15] BODY MASS INDEX DOES NOT IMPACT ON MOLECULAR RESPONSE RATE OF CHRONIC MYELOID LEUKEMIA (CML) TREATED FRONTLINE WITH SECOND GENERATION TKIS
    Molica, M.
    Canichella, M.
    Colafigli, G.
    Diverio, D.
    Latagliata, R.
    Alimena, G.
    Foa, R.
    Breccia, M.
    HAEMATOLOGICA, 2017, 102 : 88 - 88
  • [16] The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations
    Soysal, Teoman
    Eskazan, Ahmet Emre
    Serin, Istemi
    Sadri, Sevil
    Keskin, Dilek
    Yurttas, Nurgul Ozgur
    Berk, Selin
    Ozunal, Isil Erdogan
    Salihoglu, Ayse
    Ar, Muhlis Cem
    Ongoren, Seniz
    Baslar, Zafer
    Ozbek, Ugur
    Aydin, Yildiz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (07): : E377 - E384
  • [17] EFFICACY AND SAFETY OF PONATINIB USED IN FRAIL CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS OUTSIDE OF CLINICAL TRIALS
    Breccia, M.
    Abruzzese, E.
    Accurso, V.
    Castagnetti, F.
    Galimberti, S.
    Bonifacio, M.
    Gangemi, D.
    La Barba, G.
    Sora, F.
    Tiribelli, M.
    Iurlo, A.
    Luciano, L.
    Gozzini, A.
    Pezzullo, L.
    Rossi, A. Russo
    Sgherza, N.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 89 - 90
  • [18] Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials
    Yilmaz, Musa
    Kantarjian, Hagop
    Jabbour, Elias
    O'Brien, Susan
    Borthakur, Gautam
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Burger, Jan
    Pierce, Sherry
    Quintas-Cardama, Alfonso
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (06): : 693 - 699
  • [19] Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
    Hughes, Timothy P.
    Saglio, Giuseppe
    Kantarjian, Hagop M.
    Guilhot, Francois
    Niederwieser, Dietger
    Rosti, Gianantonio
    Nakaseko, Chiaki
    De Souza, Carmino Antonio
    Kalaycio, Matt E.
    Meier, Stephan
    Fan, Xiaolin
    Menssen, Hans D.
    Larson, Richard A.
    Hochhaus, Andreas
    BLOOD, 2014, 123 (09) : 1353 - 1360
  • [20] Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events
    Molica, Matteo
    Scalzulli, Emilia
    Colafigli, Gioia
    Fegatelli, Danilo Alunni
    Massaro, Fulvio
    Latagliata, Roberto
    Foa, Robin
    Breccia, Massimo
    ANNALS OF HEMATOLOGY, 2018, 97 (10) : 1803 - 1808
12345